Clinical Cancer Research · 2006 · 177 citations · 16 references
In summary, we have identified AS negativity as a frequent event in MPM in vivo, leading to susceptibility to cytotoxicity following restriction of arginine. A phase II clinical trial is planned to evaluate the role of arginine depletion in patients with AS-negative MPM.
16
Yong Xia, Valina L. Dawson, Ted M. Dawson et al. · Proceedings of the National Academy of Sciences · 1996 · 722 citations · Full text
Incidence and distribution of argininosuccinate synthetase deficiency in human cancers
Brian J. Dillon, Víctor G. Prieto, Steven A. Curley et al. · Cancer · 2004 · 330 citations